Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALLJordan Gauthier, Cameron J. Turtle, Mazyar Shadman et al.|Blood Advances|2025Cited by 10
Novel antibodies for identification, selection, and manipulation of T cells expressing Whitlow linker-containing CARsErik L. Kimble, Cameron J. Turtle, Jocelyn H. Wright et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 2
139 | ENHANCED CAR T‐CELL EXPANSION AND DURABLE COMPLETE RESPONSES WITH NKTR‐255 PLUS LISOCABTAGENE MARALEUCEL IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMAAlexandre V. Hirayama, Cameron J. Turtle, Jordan Gauthier et al.|Hematological Oncology|2025Cited by 1
Phase 2 Trial of SC Versus IV Anakinra to Prevent CRS and Neurotoxicity in LBCL Patients Receiving Lisocabtagene Maraleucel: Final Analysis and Comparison to Historical ControlEmily C. Liang, Jordan Gauthier, Jennifer J. Huang et al.|Transplantation and Cellular Therapy|2025Cited by 0
25 Novel antibodies for identification, selection, and manipulation of T cells expressing Whitlow linker-containing CARsErik L. Kimble, Cameron J. Turtle, Jocelyn H. Wright et al.|Regular and Young Investigator Award Abstracts|2025Cited by 0